

# HUMAN PYY (Total) RIA KIT 125 TUBES (Cat. # PYYT-66HK)

I.	Intended Use	2
II.	Principles Of Procedure	2
III.	Reagents Supplied	3
IV.	Storage and Stability	4
٧.	Reagent Precautions	4
VI.	Materials Required But Not Provided	5
VII.	Specimen Collection And Storage	5
VIII.	Assay Procedure	6
IX.	Calculations	9
Χ.	Interpretation	9
XI.	Assay Characteristics	10
XII.	Quality Controls	12
XIII.	References	12
۲IV.	Replacement Reagents	12
XV.	Ordering Information	13

## Human PYY (Total) RIA KIT 125 TUBES (Cat. # PYYT-66HK)

#### I. INTENDED USE

Peptide YY (P-YY), a novel 36 amino-acid amidated hormone is a component of the complex neuroendocrine control process. This gut hormone (fragment 3-36) when infused into subjects has been shown to reduce food intake in normal weight and obese individuals. PYY infusion also reduced the plasma levels of the hunger-promoting hormone ghrelin. PYY levels have been shown to drop pre-meal and then increase post prandially. In circulation, PYY exists at least in two molecular forms: 1-36 and 3-36.

Millipore's PYY (Total) Radioimmunoassay (RIA) Kit utilizes an antibody, which recognizes both the 1-36 and 3-36 forms of Human PYY. Sensitivity of 10 pg/mL can easily be achieved when using a 100 $\mu$ l serum or plasma sample in a two-day, disequilibrium assay (400  $\mu$ l Total Volume). *This kit is for research purposes only.* 

### II. PRINCIPLES OF PROCEDURE

In radioimmunoassay, a fixed concentration of labeled tracer antigen is incubated with a constant dilution of antiserum such that the concentration of antigen binding sites on the antibody is limited, for example, only 40%-50% of the total tracer concentration may be bound by antibody. If unlabeled antigen is added to this system, there is competition between labeled tracer and unlabeled antigen for the limited and constant number of binding sites on the antibody. Thus, the amount of tracer bound to antibody will decrease as the concentration of unlabeled antigen increases. This can be measured after separating antibody-bound from free tracer and counting one or the other, or both fractions. A standard curve is set up with increasing concentrations of standard unlabeled antigen and from this curve the amount of antigen in unknown samples can be calculated. Thus, the four basic necessities for a radioimmunoassay system are: a specific antiserum to the antigen to be measured, the availability of a radioactive labeled form of the antigen, a method whereby antibody-bound tracer can be separated from the unbound tracer, and finally, an instrument to count radioactivity.

The Millipore PYY (Total) assay utilizes <sup>125</sup>I-labeled PYY and a PYY antiserum to determine the level of total PYY in serum, plasma or tissue culture media by the double antibody/PEG technique.

#### III. REAGENTS SUPPLIED

Each kit is sufficient to run 125 tubes and contains the following reagents.

### A. Assay Buffer

A buffer containing BSA and 0.08% sodium azide

Quantity: 2 bottles, 25 mL/vial Preparation: Ready to use

### B. Human PYY (Total) Antibody

Guinea Pig anti-PYY Serum in Assay Buffer

Quantity: 13 mL/vial Preparation: Ready to use

# C. <sup>125</sup>I-Human PYY

 $^{125}$ I-PYY Label, HPLC purified (specific activity 302  $\mu$ Ci/ $\mu$ g)

Lyophilized for stability. Freshly iodinated label contains <1.5 μCi (56 kBq),

calibrated to the 1st Monday of each month.

Quantity: 13.5 mL/vial upon hydration

Preparation: Contents Lyophilized. Hydrate with 13.5mL of Assay Buffer. Allow to

set at room temperature for 30 minutes, with occasional gentle mixing.

### D. Human PYY Standards

Synthetic lyophilized PYY in Assay Buffer

Lyophilized for stability.

Quantity: 2 mL/vial upon hydration

Preparation: Contents Lyophilized. Hydrate with 2 mL distilled or deionized water. The actual concentration of PYY present in the vial will be lot-dependent. Please refer to the analysis sheet for exact PYY concentration present in a specific lot.

# E. Human PYY (Total) Quality Controls 1 & 2

Synthetic lyophilized PYY in Assay Buffer.

Lyophilized for stability.

Quantity: 1 mL/vial upon hydration

Preparation: Contents Lyophilized. Hydrate with 1 mL distilled or deionized water.

# F. Guinea Pig Carrier

Normal Guinea Pig Serum

Quantity: 2 mL/vial

Preparation: Ready to use

### G. Precipitating Reagent

Goat anti-Guinea Pig IgG Serum, 3% PEG and 0.05% Triton X-100 in 0.05M

Phosphosaline, 0.025M EDTA, 0.08% Sodium Azide

Quantity: 130 mL/vial

Preparation: Ready to use; chill to 4℃.

#### IV. STORAGE AND STABILITY

Refrigerate all reagents between 2 and 8 °C for short-term storage. For prolonged storage (>2 weeks), freeze at  $\leq$  -20 °C. Avoid multiple (>5) freeze/thaw cycles. Refer to date on bottle for expiration when stored at  $\leq$  -20 °C. Do not mix reagents from different kits unless they have the same lot number. Store remaining hydrated Standard, Quality Controls and Tracer at -20 °C.

#### V. REAGENT PRECAUTIONS

#### A. Radioactive Materials

This radioactive material may be received, acquired, possessed and used only by research personnel or clinical laboratories for in vitro research tests not involving internal or external administration of the material, or the radiation there from to human beings or animals. Its receipt, acquisition, possession, use and transfer are subject to the regulations of the U. S. Nuclear Regulatory Commission (NRC) or of a State with which the Commission has entered into an agreement for the exercise of regulatory authority.

The following are suggested general rules for the safe use of radioactive material. The customer's Radiation Safety Officer is ultimately responsible for the safe handling and use of radioactive material.

- Wear appropriate personal devices at all times while in areas where radioactive materials are used or stored.
- 2. Wear laboratory coats, disposable gloves, and other protective clothing at all times.
- 3. Monitor hands, shoes, and clothing and immediate area surrounding the workstation for contamination after each procedure and before leaving the area.
- 4. Do not eat, drink, or smoke in any area where radioactive materials are stored or used.
- 5. Never pipette radioactive material by mouth.
- 6. Dispose of radioactive waste in accordance with NRC rules and regulations.
- 7. Avoid contaminating objects such as telephones, light switches, doorknobs, etc.
- 8. Use absorbent pads for containing and easily disposing of small amounts of contamination.
- 9. Wipe up all spills immediately and thoroughly and dispose of the contaminated materials as radioactive waste. Inform Radiation Safety Officer.

## V. REAGENT PRECAUTIONS (continued)

#### B. Sodium Azide

Sodium Azide has been added to all reagents as a preservative at a concentration of 0.08%. Although it is at a minimum concentration, Sodium Azide may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build up.

#### VI. MATERIALS REQUIRED BUT NOT PROVIDED

- 1. Borosilicate glass tubes, 12 x 75 mm. (NOTE: Polypropylene or polystyrene tubes may be used if the pellet formation is acceptably stable.)
- 2. 100 μL pipette with disposable tips
- 3. 10 μL, 100 μL & 1.0 mL repeating dispenser
- 4. Refrigerated swing bucket centrifuge capable of developing 2,000 3,000 xg. (Use of fixed-angle buckets is not recommended.)
- 5. Absorbent paper
- 6. Vortex mixer
- 7. Refrigerator
- 8. Gamma Counter
- 9. Aprotinin (recommended in SPECIMEN COLLECTION AND STORAGE section)

#### VII. SPECIMEN COLLECTION AND STORAGE

Note: Samples should be processed as quickly as possible and kept on ice to retard the breakdown of PYY. We recommend treatment of the blood with Aprotinin at a final concentration of 500 KIU/mL of blood. For total PYY measurement using this RIA, DPP-IV inhibitor is not required. However for future measurement of 3-36 PYY with the same set of samples we suggest the addition of 10  $\mu L$  of DPP-IV inhibitor per one mL of blood along with the aprotinin.

- 1. A maximum of 100  $\mu$ L per assay tube of serum or plasma should be used. Tissue culture and other media may also be used.
- Care must be taken when using heparin as an anticoagulant, since excess will
  provide falsely high values. Use no more than 10 IU heparin per mL of blood
  collected.
- 3. For longer storage, specimens should be aliquot and stored at ≤ 20°C or below. Multiple freeze/thaw cycles should be avoided.
- 4. Avoid using samples with gross hemolysis or lipemia.

#### VIII. ASSAY PROCEDURE

For optimal results, accurate pipetting and adherence to the protocol are recommended.

### A. PYY Standard Preparation

Use care in opening the lyophilized Standard vial. Using a pipette, reconstitute the PYY Standard with **2 mL** distilled or deionized water into the glass vial to give a concentration prescribed in the analysis sheet. Invert and mix gently, let sit for five minutes or until completely dissolved then mix well.

Label seven glass tubes 1, 2, 3, 4, 5, 6 and 7. Add 0.5 mL Assay Buffer to each of the seven tubes. Prepare serial dilutions by adding 0.5 mL of the reconstituted standard to tube 1, mix well and transfer 0.5 mL of tube 1 to tube 2, mix well and transfer 0.5 mL of tube 3 to tube 4, mix well and transfer 0.5 mL of tube 4 to tube 5, mix well and transfer 0.5 mL of tube 5 to tube 6, mix well and transfer 0.5 mL of tube 5 to tube 7 and mix well.

Note: Do not use a Repeater pipette. Change tip for every dilution. Wet tip with Standard before dispensing. Unused portions of standard should be stored at ≤ -20 °C. Avoid multiple freeze/thaw cycles.

Standard Concentration pg/mL	Volume of Deionized Wate to Add	Volume of Standard to Add
X (Refer to analysis sheet for exact concentration)	2 mL	0

	Standard Concentration	Volume of Assay Buffer	Volume of Standard
Tube #	pg/mL	to Add	to Add
1	X/2	0.5 mL	0.5 mL of reconstituted standard
2	X/4	0.5 mL	0.5 mL of tube 1
3	X/8	0.5 mL	0.5 mL of tube 2
4	X/16	0.5 mL	0.5 mL of tube 3
5	X/32	0.5 mL	0.5 mL of tube 4
6	X/64	0.5 mL	0.5 mL of tube 5
7	X/128	0.5 mL	0.5 mL of tube 6

# B. PYY Quality Control 1 and 2 Preparation

1. Use care in opening the lyophilized Quality Control vials. Using a pipette, reconstitute each of the PYY Quality Control 1 and Quality Control 2 with **1 mL** distilled or deionized water into the glass vials. Invert and mix gently, let sit for five minutes or until completely dissolved then mix well.

Note: For exact concentration of Quality Control 1 and 2, refer to Analysis Sheet. Unused portions of Quality Controls should be stored at ≤ -20 °C. Avoid multiple freeze/thaw cycles.

## **VIII. ASSAY PROCEDURE (continued)**

### Day One

- 1. Pipette 300  $\mu$ L of Assay Buffer to the Non-Specific Binding (NSB) tubes (3-4). Pipette 200  $\mu$ L of Assay Buffer in the Reference (Bo) tubes (5-6). Pipette 100  $\mu$ L of Assay Buffer to tubes seven through the end of the assay.
- 2. Pipette 100  $\mu$ L of Standards and Quality Controls in duplicate (see assay flow chart).
- 3. Pipette 100  $\mu$ L of each sample in duplicate. (NOTE: Smaller volumes of sample may be used when PYY concentrations are anticipated to be elevated or when sample size is limited. Additional Assay Buffer should be added to compensate for the difference so that the volume is equivalent to 100  $\mu$ L (e.g., when using 50  $\mu$ L of sample, add 50  $\mu$ L of Assay Buffer). Refer to Section IX for calculation modification.
- 4. Pipette 100  $\mu$ L of PYY Antibody to all tubes except Total Count tubes (1-2) and NSB tubes (3-4).
- 5. Vortex, cover, and incubate overnight (20-24 hours) at 4°C.

### **Day Two**

- 6. Hydrate the  $^{125}$ I-PYY tracer with 13.5 mL of Assay Buffer and gently mix. Pipette 100  $\mu$ L of  $^{125}$ I-PYY to all tubes.
- 7. Vortex, cover and incubate overnight (22-24 hours) at 4°C.

### **Day Three**

- 8. Add 10 μL of Guinea Pig Carrier to all tubes except Total Count tubes (1-2).
- 9. Add 1.0 mL of cold (4°C) Precipitating Reagent to all tubes except Total Count tubes (1-2).
- 10. Vortex and incubate 20 minutes at 4℃.
- 11. Centrifuge, at 4°C, for 20 minutes at 2,000-3,000 xg. Note: If less than 2,000 xg is used, the time of centrifugation must be increased to obtain a firm pellet (e.g. 40 minutes). Multiple centrifuge runs within an assay must be consistent. Conversion of rpm to xg:

$$xg = (1.12 \times 10^{-5}) (r) (rpm)^2$$
  
r = radial distance in cm (from axis of rotation to the bottom of the tube)  
rpm = revolutions per minute

12. Immediately decant supernatant from all centrifuged tubes except Total Count tubes (1-2). Drain tubes for 15-60 seconds (be consistent between racks), blot excess liquid from lip of tubes and count pellet using the gamma counter according to the manufacturer's instructions.

# **Assay Procedure Flow Chart**

Day One				Day Two Day Three					
Set-up	Step 1	Step 2&3	Step 4	Step 5	Step 6	Step 7	Step 8	Step 9	Steps 10-12
Tube Number	Add Assay Buffer	Add Standard/QC/ Sample	Add PYY Antibody	4°C	Add I-125 PYY Tracer	4°C	Add Guinea Pig Carrier	Add Precipitating Reagent	Centrifuge at 4°C for 20 min and Count
1,2	-	-	-	s at	100 μl	at	-		fo
3,4	300 μl	-	-	hrs	100 µl	hrs	10 μl	1.0 mL	.t
5,6	200 μΙ	-	100 μl	24	100 µl	24	10 μl	1.0 mL	at 4
7,8	100 μl	100 μl of tube 7	100 μl	50-	100 µl	5.	10 µl	1.0 mL	ge
9,10	100 μl	100 μl of tube 6	100 μl	te ;	100 µl	<u>e</u>	10 µl	1.0 mL	rifuge Count
11,12	100 μl	100 μl of tube 5	100 μl	lba	100 µl	bai	10 μl	1.0 mL	ntr d O
13,14	100 μl	100 μl of tube 4	100 μl	າວເ	100 μl	no	10 μl	1.0 mL	Cent and
15,16	100 μl	100 μl of tube 3	100 μl	<u> </u>	100 μl	트	10 μl	1.0 mL	
17,18	100 μl	100 μl of tube 2	100 μl	anc	100 μl	) I	10 μl	1.0 mL	at 4°C, Decant
19,20	100 μl	100 μl of tube 1	100 μl	ř.	100 μl	<u>e</u> .	10 μl	1.0 mL	—
21,22	100 μl	100 µl of reconstituted standard	100 μl	ex, Cover, and Incubate 20-24 hrs	100 μl	Vortex, Cover and Incubate 22-24 hrs at	10 μΙ	1.0 mL	Incubate 20 min.
23,24	100 μl	100 μl of QC 1	100 μl	Vortex,	100 μl	ort o	10 μΙ	1.0 mL	ate
25,26	100 μl	100 μl of QC 2	100 μl	) ×	100 μl	) >	10 μΙ	1.0 mL	ğn
27,n	100 μl	100 μl of unknown	100 μl		100 μl		10 μΙ	1.0 mL	lnc

#### IX. CALCULATIONS

## A. Explanation

The calculations for PYY can be automatically performed by most gamma counters possessing data reduction capabilities or by independent treatment of the raw data using a commercially available software package. Choose weighted 4-parameter or weighted log/logit for the mathematical treatment of the data. [NOTE: Be certain the procedure used subtracts the NSB counts from each average count, except Total Counts, prior to final data reduction.]

#### B. Manual Calculation

- 1. Average duplicate counts for Total Count tubes (1-2), NSB tubes (3-4), Total Binding tubes (reference, Bo)(5-6), and all duplicate tubes for standards and samples to the end of the assay.
- 2. Subtract the average NSB counts from each average count (except for Total Counts). These counts are used in the following calculations.
- 3. Calculate the percentage of tracer bound

(Total Binding Counts/Total Counts) X 100 This should be 35-50%.

4. Calculate the percentage of total binding (%B/Bo) for each standard and sample

%B/Bo = (Sample or Standard/Total Binding ) X 100

- 5. Plot the % B/Bo for each standard on the y-axis and the known concentration of the standard on the x-axis using log-log graph paper.
- 6. Construct the reference curve by joining the points with a smooth curve.
- 7. Determine the pg/mL of PYY in the unknown samples and controls by interpolation of the reference curve.

[NOTE: When sample volumes assayed differ from 100  $\mu$ l, an appropriate mathematical adjustment must be made to accommodate for the dilution factor (e.g., if 50  $\mu$ l of sample is used, then calculated data must be multiplied by 2).]

#### X. INTERPRETATION

#### A. Acceptance Criteria

- 1. The run will be considered accepted when all Quality Control values fall within the calculated Quality Control Range; if any QC's fall outside the control range, review results with the supervisor.
- 2. If the difference between duplicate results of a sample is >10% CV, repeat the sample.

#### XI. ASSAY CHARACTERISTICS

### A. Sensitivity

The lowest level of PYY that can be detected by this assay is 10 pg/mL when using a  $100\mu$ L sample size.

#### B. Performance

The following parameters of assay performance are expressed as Mean  $\pm$  Standard Deviation.

 $ED_{80} = 36 \pm 5$   $ED_{50} = 103 \pm 12$  $ED_{20} = 300 \pm 38$ 

# C. Specificity

The specificity (also known as selectivity) of an analytical test is its ability to selectively measure the analyte in the presence of other like components in the sample matrix.

### **PYY RIA**

Crossreactivity	
PYY 1-36 human	100%
PYY 3-36 human	100%
[Pro34] PYY	100%
[Leu31, Pro34] PYY	100%
Rat/Porcine PYY 1-36	<0.1%
Rat/Porcine PYY 3-36	<0.1%
HPPP	<0.1%
NPY	<0.1%
Human Leptin	*
Glucagon	*
Human Ghrelin	*
Human Insulin	*
GLP-1	*

<sup>\*-</sup>Not detectable

#### D. Precision

Within and Between Assay Variation

Sample no.	Mean pg/mL	Within %CV	Between %CV
1	82.7	9.4	8.5
2	111.1	2.9	7.1
3	542.6	3.6	5.5

Within and between assay variations were performed on three human plasma samples containing varying concentrations of Human PYY. Data (mean and %CV) shown are from one assay with eight duplicate determinations of each plasma sample for intra-assay precision. For inter-assay precision, data are generated using eight separate assays run for the three samples in duplicate.

## XI. ASSAY CHARACTERISTICS (continued)

### E. Recovery

Spike and Recovery of PYY in Human Plasma

Sample No.	PYY added pg/mL	%Recovery
1	40	111
2	320	96
3	1280	83

Varying concentrations of Human PYY were added to three different human plasma samples and the PYY content was determined by RIA. Mean of the observed levels from duplicate determinations in one assay are shown. Percent recovery was calculated as the observed over expected multiplied by 100.

# F. Linearity

Effect of Plasma Dilution

Sample No.	Volume sampled	Observed pg/mL	Expected pg/mL	% Expected
1	100µl	161	161	100
	75µl	162		101
	50µl	170		105
	25µl	180		112
2	100µl	156	156	100
	75µl	167		107
	50µl	169		108
	25µl	179		115
3	100µl	199	199	100
	75µl	220		111
	50µl	217		109
	25µl	246		124
4	100µl	124	124	100
	75µl	125		101
	50µl	133		107
	25µl	155		125

Aliquots of pooled Human Plasma containing varying concentrations of PYY were analyzed in the volumes indicated. Dilution factors of 1, 1.33, 2, and 4 representing 100µl, 75µl, 50µl, and 25µl respectively, were applied in calculating observed concentrations.

#### XII. QUALITY CONTROLS

Good laboratory practice requires that quality control specimens be run with each standard curve to check the assay performance. Two levels of controls are provided for this purpose. These and any other control materials should be assayed repeatedly to establish mean values and acceptable ranges. Each individual laboratory is responsible for defining their system for quality control decisions and is also responsible for making this system a written part of their laboratory manual. The ranges for Quality Control 1 and 2 are provided on the card insert or can be located at the Millipore website www.millipore.com/bmia.

Recommended batch analysis decision using two controls (Westgard Rules<sup>4</sup>):

- When both controls are within ±2 SD.
   Decision: Approve batch and release analyte results.
- 2. When one control is outside ±2 SD and the second control is within ±2 SD. Decision: Hold results, check with supervisor. If no obvious source of error is identified by the below mentioned check of systems, the supervisor may decide to release the results.

Technician check of systems:

- 1. Check for calculation errors
- 2. Repeat standards and controls
- 3. Check reagent solutions
- 4. Check instrument

### XIII. REFERENCES

- 1. Morgan, C.R. and Lazarow, A. Immunoassay of Insulin: Two antibody system. Plasma insulin levels in normal, Subdiabetic, and diabetic rats. Diabetes 12:115-126, 1963.
- 2. Thorell, J.I. Scand. J. Clin. Lab. Invest. 31:187, 1973.
- 3. Feldman, H. and Rodbard, D. "Mathematical Theory of Radioimmunoassay", in: W.D. Odell and Doughaday, W.H. (Ed.), <u>Principles of Competitive Protein-Binding Assays</u>. Philadelphia: J.B. Leppincott Company; pp 158-203, 1971.
- 4. Westgard, J.O., et. al. A multi-rule Shewhart chart for quality control in clinical chemistry. *Clin. Chem.* 27:493-501, 1981.

### XIV. REPLACEMENT REAGENTS

Reagent	Cat #
<sup>125</sup> I-Human PYY (<1.5 μCi, 56 kBq)	9066-HK
Guinea Pig Carrier (2 mL)	GPC-HK
Human PYY Standard	8066-K
Human PYY (Total) Antibody (13 mL)	1066-HK
Precipitating Reagent (130 mL)	PR-UVHK
Human PYY Quality Control 1&2 (1 mL each)	6066-K
Assay Buffer (25 mL)	AB-66HK

#### XV. ORDERING INFORMATION

### A. To place an order:

#### For USA Customers:

Please provide the following information to our customer service department to expedite your telephone, fax or mail order:

- 1. Your name, telephone and/or fax number
- 2. Customer account number
- 3. Shipping and billing address
- 4. Purchase order number
- 5. Catalog number and description of product
- 6. Quantity and product size

NOTE: Appropriate license from NRC (or equivalent) must be on file at Millipore before radioactive orders can be shipped.

**TELEPHONE ORDERS:** 

Toll Free US (866) 441-8400

(636) 441-8400

FAX ORDERS: (636) 441-8050

MAIL ORDERS: Millipore

6 Research Park Drive

St. Charles, Missouri 63304 U.S.A.

#### For International Customers:

To best serve our international customers, it is Millipore's policy to sell our products through a network of distributors. To place an order or to obtain additional information about Millipore products, please contact your local distributor.

#### B. Conditions of Sale

All products are for research or manufacturing use only. They are not intended for use in clinical diagnosis or for administration to humans or animals. All products are intended for *in vitro* use only.

#### C. Material Safety Data Sheets (MSDS)

Material safety data sheets for Millipore products may be ordered by fax or phone. See Section A above for details on ordering.